| 4G0V | date | ![]() |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| authors | |||||||||||||||
| compound | source | ||||||||||||||
| symmetry |
| ||||||||||||||
| crystal cell |
| ||||||||||||||
| method | X-Ray Diffraction | resolution | |||||||||||||
| ligand | MG, MIX | enzyme |
| ||||||||||||
| Gene Ontology |
| ||||||||||||||
| Primary reference | On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs., Wu CC, Li YC, Wang YR, Li TK, Chan NL, Nucleic Acids Res. 2013 Sep 14. PMID:24038465 | ||||||||||||||
| Data retrieval |
![]() |
| View 4G0V in 3D |
Proteopedia, because life has more than 2D. |
| Structure-derived information |
| Sequence-derived information |
|
OCA© by Jaime Prilusky, 1996-2014,2022,2024 Bioinformatics Unit Weizmann Institute of Science |